185 related articles for article (PubMed ID: 35872531)
1. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
Cannataro VL; Kudalkar S; Dasari K; Gaffney SG; Lazowski HM; Jackson LK; Yildiz I; Das RK; Gould Rothberg BE; Anderson KS; Townsend JP
Lung Cancer; 2022 Sep; 171():34-41. PubMed ID: 35872531
[TBL] [Abstract][Full Text] [Related]
2. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
[TBL] [Abstract][Full Text] [Related]
3. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.
Cannataro VL; Gaffney SG; Sasaki T; Issaeva N; Grewal NKS; Grandis JR; Yarbrough WG; Burtness B; Anderson KS; Townsend JP
Oncogene; 2019 May; 38(18):3475-3487. PubMed ID: 30647454
[TBL] [Abstract][Full Text] [Related]
4. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Henderson S; Chakravarthy A; Su X; Boshoff C; Fenton TR
Cell Rep; 2014 Jun; 7(6):1833-41. PubMed ID: 24910434
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
6. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
8. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
9. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
10. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
11. Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B.
Adolph MB; Love RP; Feng Y; Chelico L
Nucleic Acids Res; 2017 Nov; 45(20):11925-11940. PubMed ID: 28981865
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Shigaki H; Kurashige J; Hiyoshi Y; Iwatsuki M; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Oki E; Watanabe M; Baba H
Med Oncol; 2016 Mar; 33(3):26. PubMed ID: 26880326
[TBL] [Abstract][Full Text] [Related]
13. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
14. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
16. Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.
Fanourakis G; Tosios K; Papanikolaou N; Chatzistamou I; Xydous M; Tseleni-Balafouta S; Sklavounou A; Voutsinas GE; Vastardis H
Exp Mol Pathol; 2016 Dec; 101(3):314-319. PubMed ID: 27818121
[TBL] [Abstract][Full Text] [Related]
17. APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.
Lindley RA; Hall NE
Mutat Res; 2018 Jul; 810():33-38. PubMed ID: 29957488
[TBL] [Abstract][Full Text] [Related]
18. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
[TBL] [Abstract][Full Text] [Related]
19. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
20. The APOBEC-2 crystal structure and functional implications for the deaminase AID.
Prochnow C; Bransteitter R; Klein MG; Goodman MF; Chen XS
Nature; 2007 Jan; 445(7126):447-51. PubMed ID: 17187054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
